Quince Therapeutics Updates Business Post‑Orphai Acquisition

What Happened Quince Therapeutics, Inc. (QNCX) filed an 8-K on July 30, 2026 (Item 8.01) providing an updated “Business” description and updated “Risk Factors” reflecting the company’s operations after its acquisition of Orphai. The filing also (Item 9.01) attaches Orphai’s historical financial statements — audited for the years ended December 31, 2025 and 2024 and unaudited interim condensed consolidated financial statements for the three months ended March 31, 2026 and 2025 — as exhibits.

Key Details

• The post-acquisition business description is attached as Exhibit 99.4 and incorporated by reference.
• Updated risk factors relating to the combined company are attached as Exhibit 99.5 and incorporated by reference.
• Orphai’s audited financial statements for fiscal years ended Dec. 31, 2025 and Dec. 31, 2024 are included.
• Orphai’s unaudited interim condensed consolidated financial statements for the three months ended Mar. 31, 2026 and Mar. 31, 2025 are included.

Why It Matters This 8-K gives investors the formal, SEC‑filed view of how Quince’s business and risk profile look after acquiring Orphai and provides the acquired company’s recent financial history. Investors should review the updated business description, risk factors and Orphai’s financials to understand how the acquisition may change Quince’s strategy, operations and financial baseline. The filing does not itself provide new operating results or forward guidance for Quince.